Results 211 to 220 of about 70,258 (243)
Coptis chinensis extracellular vesicles loaded with CA1-siRNA promote endothelial repair and stent restenosis therapy by regulating the PADI2 and NF-κB pathway. [PDF]
J NanobiotechnologyWang X +12 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Journal of the American Academy of Nurse Practitioners, 1996
Return of angina within 6 months of a catheter-based treatment of coronary artery disease usually reflects restenosis due to an overly aggressive local healing response to the procedure-related arterial injury. The restenotic lesion should be treated aggressively.
C, Brown +5 more
openaire +2 more sources
Return of angina within 6 months of a catheter-based treatment of coronary artery disease usually reflects restenosis due to an overly aggressive local healing response to the procedure-related arterial injury. The restenotic lesion should be treated aggressively.
C, Brown +5 more
openaire +2 more sources
Costs of coronary restenosis (Lovastatin Restenosis Trial)
The American Journal of Cardiology, 1996Within the Lovastatin Restenosis Trial, restenosis has been clearly shown to increase resource utilization and costs. While it is not possible to generalize these results to other patient populations, it is clear that successful efforts to decrease restenosis will certainly improve efficacy while decreasing follow-up costs and increasing the cost ...
S P, Gilbert +3 more
openaire +2 more sources
Interventional Cardiology Clinics, 2022
In-stent restenosis (ISR) remains a potential complication after percutaneous coronary intervention, even in the era of drug-eluting stents, and its treatment remains suboptimal. Neoatherosclerosis is an important component of the pathology of ISR and is accelerated in drug-eluting stents compared with bare-metal stents.
Kenji, Kawai +2 more
openaire +2 more sources
In-stent restenosis (ISR) remains a potential complication after percutaneous coronary intervention, even in the era of drug-eluting stents, and its treatment remains suboptimal. Neoatherosclerosis is an important component of the pathology of ISR and is accelerated in drug-eluting stents compared with bare-metal stents.
Kenji, Kawai +2 more
openaire +2 more sources
Current Treatment Options in Cardiovascular Medicine, 2001
Angiographic restenosis occurs in 30% to 50% of patients after percutaneous transluminal coronary angioplasty (PTCA) with 20% to 30% target vessel revascularization at one year, and is associated with increased morbidity, mortality and health care costs. Intracoronary stents are the first line of therapy against restenosis after angioplasty.
Mehran, Moussavian +2 more
openaire +2 more sources
Angiographic restenosis occurs in 30% to 50% of patients after percutaneous transluminal coronary angioplasty (PTCA) with 20% to 30% target vessel revascularization at one year, and is associated with increased morbidity, mortality and health care costs. Intracoronary stents are the first line of therapy against restenosis after angioplasty.
Mehran, Moussavian +2 more
openaire +2 more sources
Interventional Cardiology Clinics, 2016
In-stent restenosis (ISR) is the narrowing of a stented coronary artery lesion. The mean time from percutaneous coronary intervention (PCI) to ISR was 12 months with drug-eluting stents (DES) and 6 months with bare metal stents (BMS). ISR typically presents as recurrent angina. The use of DES has significantly reduced the rate of ISR compared with BMS.
Michael S, Lee, Gaurav, Banka
openaire +2 more sources
In-stent restenosis (ISR) is the narrowing of a stented coronary artery lesion. The mean time from percutaneous coronary intervention (PCI) to ISR was 12 months with drug-eluting stents (DES) and 6 months with bare metal stents (BMS). ISR typically presents as recurrent angina. The use of DES has significantly reduced the rate of ISR compared with BMS.
Michael S, Lee, Gaurav, Banka
openaire +2 more sources